FMP
Enter
API Tools
Extras
Protagenic Therapeutics, Inc.
PTIX
NASDAQ
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
0.3 USD
0.0412 (13.73%)
WACOC
Price
0.3
Beta
Diluted Shares Outstanding
4.9M
Costof Debt
4.15
Tax Rate
After Tax Cost Of Debt
4.15
Risk Free Rate
Market Risk Premium
Cost Of Equity
Total Debt
0
Total Equity
1.47M
Total Capital
1.47M
Debt Weighting
0
Equity Weighting
100
Wacc
5.8
